1083010-47-2

Upstream product

• 1539-42-0 bis[(2-pyridyl)methyl]amine 
• 135990-12-4 3,5-bis(bromomethyl)phenol 
• 39630-68-7 diethyl 5-hydroxyisophthalate 
• 153707-56-3 3,5-bis(hydroxymethyl)phenol 
• 618-83-7 5-Hydroxyisophthalic acid 
• 13036-02-7 Dimethyl 5-hydroxyisophthalate 
• 1374350-37-4 1,3-bis(chloromethyl)-5-(ethoxymethoxy)benzene 
• 1374350-36-3 [5-(ethoxymethoxy)-1,3-phenylene]dimethanol 
• 1374350-35-2 dimethyl 5-(ethoxymethoxy)isophthalate 
• 1374350-39-6 [5-(ethoxymethoxy)benzene-1,3-diyl]bis[N,N-bis(pyridin-2-ylmethyl)methanamine] 

Downstream Products

• 1374350-40-9 ((C₅H₄NCH₂)2NCH₂)2C₆H₃OC₃H₆(CH₂COOC(CH₃)3)3(CH₂)8N₄ 

Relevant academic research and scientific papers

In-situ generation of differential sensors that fingerprint kinases and the cellular response to their expression

Mitogen-activated protein (MAP) kinases are responsible for many cellular functions, and their malfunction manifests itself in several human diseases. Usually, monitoring the phosphorylation states of MAP kinases in vitro requires the preparation and puri

BACTERIA-TARGETED MAGNETIC RESONANCE CONTRAST AGENTS

The present invention relates to bacteria-targeted contrast agents for magnetic resonance imaging (MRI). In particular, the present invention relates to bacteria targeted MRI contrast agents that can be used to detect bacteria in vivo or in vitro. In certain embodiments, the contrast agents comprise a metal chelate conjugated to at least two Zn-dipicolylamine groups.

Synthesis, characterization, and in vitro testing of a bacteria-targeted MR contrast agent

A bacteria-targeted MR contrast agent, Zn-1, consisting of two Zn-dipicolylamine (Zn-dpa) groups conjugated to a GdIII chelate has been synthesized and characterized. In vitro studies with S. aureus and E. coli show that Zn-1 exhibits a significant improvement in bacteria labeling efficiency vs. control. Studies with a structural analogue, Zn-2, indicate that removal of one Zn-dpa moiety dramatically reduces the agent's affinity for bacteria. The ability of Zn-1 to significantly reduce the T1 of labeled vs. unlabeled bacteria, resulting in enhanced MR image contrast, demonstrates its potential for visualizing bacterial infections in vivo. A bacteria-targeted MR contrast agent consisting of two Zn-dipicolylamine (Zn-dpa) groups conjugated to a Gd(III) chelate has been synthesized and characterized. This contrast agent significantly reduces the T1 of labeled versus unlabeled bacteria, resulting in enhanced MR image contrast, demonstrating its potential for visualizing bacterial infections in vivo. Copyright